💥 Dragon Pharma

LL-37

✔️ Substance: hCAP-18
✔️ Price For: Vial 5 mg
✔️ Brand: Dragon Pharma

Out of stock

Dragon Pharma LL-37

IDENTITYCompound LL-37 (hCAP-18 Active Fragment)
SubstanceHuman Cathelicidin hCAP-18
Strength5 mg
FormLyophilized Peptide Vial
Class Antimicrobial Peptide / Research Compound

PEPTIDE PROFILEPeptide TypeCathelicidin-Derived Peptide
OriginHuman Innate Immune System
Amino Acids37 Residue Active Peptide
Primary FunctionImmune Signaling & Host Defense
Research AreaRecovery & Cellular Biology

PHARMACOLOGYMechanismAntimicrobial Peptide Activity
TargetCell Membrane Interaction
PathwayInnate Immune Modulation
AdministrationResearch Peptide Protocols
Clinical StatusInvestigational

STORAGE & PACKAGEBrandDragon Pharma
Package5 mg Multi-dose Vial
Storage2–8°C Refrigerated
Before ReconstitutionKeep Lyophilized
ProtectionProtect From Light & Heat

ADMINISTRATION PROFILEAdministration Subcutaneous (SC) Research Use
PreparationReconstitution Required
Injection SiteCommon SC Areas
FrequencyBased on Research Protocol
Usage TimeShort Research Periods

DOSING INFORMATIONResearch Range100–500 mcg/day
Weekly Range0.7–3.5 mg/week
Beginner Research100 mcg/day
Intermediate Research200–300 mcg/day
Advanced Research300–500 mcg/day

USAGE PROFILETypical Duration2–8 Weeks
Initial PeriodFirst 7–14 Days
ObservationCellular Response Monitoring
Peak ResearchWeeks 3–6
StoppingNo Hormonal Withdrawal

RECOVERY PCT RequiredNo
HPTA SuppressionNot Expected
Stopping MethodDiscontinue Administration
Recovery TimeNo Testosterone Recovery Needed
MonitoringResearch Evaluation

BODYBUILDING USAGECategoryRecovery Support Research
Muscle GrowthIndirect Cellular Support
Training RecoveryResearch Interest
InflammationImmune Signaling Research
Combination Usually Studied With Recovery Compounds

MECHANISM OF ACTIONPrimary TargetCell Membrane Interaction
Immune RoleInnate Defense Signaling
Peptide FunctionHost Defense Modulation
InflammationImmune Response Regulation
Cellular EffectBiological Signaling Activity

PHARMACOKINETICSAbsorptionPeptide Dependent
DistributionSystemic Peptide Exposure
MetabolismProteolytic Breakdown
ClearancePeptide Degradation Pathways
DurationProtocol Dependent

SAFETY PROFILEToxicityLimited Human Data
Immune ResponsePossible Individual Variation
Injection RiskLocal Site Reactions
Hormonal EffectNot Anabolic Hormone
MonitoringResearch Evaluation Required

CONTRAINDICATIONSPregnancyNot Recommended
Immune DisordersMedical Evaluation Required
AllergyPeptide Sensitivity Assessment
Chronic DiseaseProfessional Assessment
MedicationInteraction Review

CHEMICAL PROFILENameLL-37 Human Cathelicidin Fragment
FormulaC205H340N60O53
Molecular Weight4493.3 g/mol
ClassAntimicrobial Peptide
Sequence37 Amino Acid Peptide

COMPATIBILITY

Recovery StackResearch Peptide Combinations

Training SupportRecovery Focused Protocols

Hormonal CompoundsNo Direct Androgen Activity

PurposeCellular Research

OVERVIEW

LL-37 is the active antimicrobial peptide fragment derived from human cathelicidin hCAP-18. It belongs to the innate immune defense system and has been studied for its interaction with microbial membranes, immune signaling pathways and cellular communication.

POTENTIAL BENEFITS

Studied antimicrobial peptide activity
Research interest in immune modulation
Potential cellular signaling effects
Recovery-related research applications
Non-androgenic peptide profile
No direct estrogenic activity
No traditional PCT requirement

POTENTIAL RISKS

Limited long-term human research data
Possible injection-site irritation
Individual immune response variation
Unknown effects outside research settings
Requires proper peptide handling
Quality depends on product source

PERFORMANCE PROFILE

Recovery Support

70%

Immune Research

85%

Direct Muscle Gain

20%

Fat Loss Effect

15%

Hormonal Activity

10%

RESEARCH TIMELINEDay 1–7 Initial peptide exposure period
Week 2–4 Cellular response observation phase
Week 4–8 Longer research evaluation period
After Discontinuation No hormonal recovery phase
PCT Not Applicable

ADMINISTRATION SUMMARYUsage Research peptide protocol
Administration Subcutaneous injection
Dose Format mcg/day research range
Duration 2–8 weeks
Vial Strength 5 mg total peptide

RECONSTITUTION PROFILEPreparation  Lyophilized peptide requires reconstitution
Diluent Research-grade peptide diluent
Storage After Mixing Refrigerated Conditions
Handling Sterile Technique Required
Stability Depends on Storage Conditions

WHAT IS DRAGON PHARMA?

Dragon Pharma is a pharmaceutical research brand known among bodybuilding and research communities for producing peptide, hormone-related and performance-oriented research products. The company focuses on laboratory-style formulations including injectable compounds, peptides and other specialized products intended for research applications.

Products associated with Dragon Pharma are commonly discussed within athletic communities because of their presentation, packaging formats and availability of specialized compounds. Product authenticity, storage conditions and responsible handling remain important factors when evaluating any research material.

WHY CHOOSE DRAGON PHARMA

Dragon Pharma products are selected by some research and bodybuilding communities due to recognizable branding, standardized vial presentation and availability of specialized compounds such as peptide-based research materials.

For peptide products like LL-37, correct storage, sterile handling and accurate labeling are important quality considerations. Users researching these compounds should evaluate product information, scientific documentation and applicable regulations before use.

CONCLUSION

Dragon Pharma LL-37 5 mg contains LL-37, the active 37-amino-acid fragment of human cathelicidin hCAP-18. Unlike anabolic hormones, LL-37 belongs to the antimicrobial peptide family and is investigated primarily for immune signaling, cellular communication and host-defense mechanisms.

Within bodybuilding and sports research communities, LL-37 is primarily discussed as a recovery-support research peptide because of interest in inflammation regulation, tissue response and biological signaling rather than direct anabolic activity.

Within bodybuilding science discussions, LL-37 is considered a recovery-oriented research compound rather than a direct muscle-building agent. Its interest among athletes comes from studies examining inflammation pathways, tissue response and biological adaptation after physical stress.

LL-37 does not function as an androgenic anabolic compound and does not require a traditional PCT protocol. Research applications should focus on scientific evaluation, correct peptide handling, storage requirements and responsible interpretation of available evidence.

DISCLAIMER

This content is provided exclusively for educational and informational purposes. LL-37 is an investigational peptide and is not approved as a bodybuilding performance-enhancing medication. This information does not represent medical advice, treatment recommendations or endorsement of non-approved usage. Always consider scientific evidence, regulations and professional guidance when evaluating pharmaceutical research compounds.